natgillin/translations-raw huggingface dataset:
Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
Enkratna podkožna ali intravenska injekcija odmerka po 0,5 mg meloksikama na kilogram telesne mase (to je 2,5 ml/100 kg telesne mase), po potrebi v kombinaciji z antibiotičnim zdravljenjem ali s peroralno rehidracijsko terapijo.
Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate.
Enkratna intramuskularna injekcija odmerka po 0,4 mg meloksikama na kilogram telesne mase (to je 2 ml/100 kg telesne mase), po potrebi v kombinaciji z antibiotičnim zdravljenjem.
Meloxidolor 20 mg/ml solution for injection for cattle, pigs and horses
Meloxidolor 20 mg/ml raztopina za injiciranje za govedo, prašiče in konje
Colourless type I glass vials of 50 ml or 100 ml, closed with a rubber stopper and sealed with an aluminium cap.
Brezbarvnime viale iz stekla tipa I po 50 ml ali 100 ml, zaprte z gumijastim zamaškom in zatesnjene z aluminijasto zaporko.
Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.
Enkratna intramuskularna injekcija v odmerku 0,4 mg meloksikama na kilogram telesne mase (t.j.0,4 ml/5 kg telesne mase) pred operacijo.
Cattle: meat and offal: 15 days; milk: 5 days Pigs:
meso in organi: 15 dni; mleko: 5 dni
Meloxidolor 20 mg/ml solution for injection for cattle, pigs and horses meloxicam
Meloxidolor 20 mg/ml raztopina za injiciranje za govedo, prašiče in konje meloksikam
Meloxidolor 5 mg/ml solution for injection for dogs, cats, cattle and pigs meloxicam
Meloxidolor 5 mg/ml raztopina za injiciranje za pse, mačke, govedo in prašiče meloksikam
Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body weight).
Enkratna intravenska injekcija odmerka po 0,6 mg meloksikama na kilogram telesne mase (to je 3 ml/100 kg telesne mase).
Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/25 kg body weight).
Enkratna intramuskularna injekcija odmerka 0,4 mg meloksikama na kilogram telesne mase (to je 2 ml/25 kg telesne mase).
Horses: meat and offal: 5 days.
meso in organi: 5 dni.
Batch {number}
Rp-Vet..
QUANTITY OF THE ACTIVE SUBSTANCE(S)
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects.
Meloksikam je nesteroidno protivnetno zdravilo (NSAID) iz skupine oksikamov.
Glycine
KARENCA
Multi-packs of 5 x 20 ml and 10 x 20 ml.
Skupna pakiranja po 5 x 20 ml in 10 x 20 ml. Ni nujno, da so v prometu vsa navedena pakiranja.
meat and offal: 5 days
meso in organi: 15 dni
Cattle: single subcutaneous or intravenous injection Pigs: single intramuscular injection Horses: single intravenous injection Read the package leaflet before use.
Govedo: enkratna subkutana ali intravenska injekcija.
20 μg/kg 65 μg/kg 65 μg/kg
20 µg/kg 65 µg/kg 65 µg/kg mišice jetra ledvice ni vnosa Protivnetna zdravila/ nesteroidna protivnetna zdravila govedo, koze
PACKAGE LEAFLET:
Meso in organi:
The European Commission issued a decision on 2 October 2009.
Evropska komisija je odločbo izdala dne 2. oktobra 2009.
Dr. Hudson (United Kingdom)
dr Hudson (Združeno kraljestvo)
Dr. Broich (Germany)
dr Broich (Nemčija)
25 June 2009
25. junij 2009
Article 29 of Directive 2001/83/EC as amended, referral on the grounds of potential serious risk to public health
1 Člen 29 Direktive 2001/83/ES Evropskega parlamenta in Sveta, kakor je bila spremenjena, napotitev zaradi možnega resnega tveganja za javno zdravje.
The company wanted the authorisation to be recognised in France and Portugal (the ‘concerned Member States').
Družba je želela, da se odobritev prizna v Franciji in na Portugalskem (zadevnih državah članicah).
London, 2 October 2009 Doc.
London, 2. oktobra 2009 Sklic dok.
However, the Member States were not able to reach an agreement and the German medicines regulatory agency referred the matter to the CHMP for arbitration on 10 October 2008.
Vendar državi članici nista mogli doseči sporazuma, zato je nemška regulatorna agencija za zdravila dne 10. oktobra 2008 zadevo napotila na CHMP v arbitražo.
Questions and answers on the referral for Octegra solution for infusion containing moxifloxacin 400 mg/250 ml
Vprašanja in odgovori v zvezi z napotitvenim postopkom za zdravilo Octegra raztopina za infundiranje, ki vsebuje moksifloksacin 400 mg/250 ml
Bayer Vital GmbH submitted Octegra solution for infusion for mutual recognition on the basis of the initial authorisation granted by Germany on 30 April 2002.
Družba Bayer Vital GmbH je predložila zdravilo Octegra raztopina za infundiranje v postopek medsebojnega priznavanja na podlagi prvotne odobritve v Nemčiji dne 30. aprila 2002.
By doing this, it stops the bacteria from growing and multiplying.
S tem zaustavi rast in razmnoževanje bakterij.
The grounds for the referral were concerns from France regarding the medicine's risk of causing problems with the heart rhythm (QT-interval prolongation).
Podlaga za napotitveni postopek so bili zadržki Francije glede tveganja zdravila za povzročanje težav s srčnim ritmom (podaljšanje intervala QT).
The review was carried out under an ‘Article 29' referral1.
Pregled je bil izveden skladno z napotitvenim postopkom iz člena 291.
It works by blocking enzymes that bacteria use to make more DNA.
Deluje tako, da zavira encime, ki jih bakterije uporabljajo za proizvodnjo dodatne DNK.
It can be used to treat the following bacterial infections: - community-acquired pneumonia (an infection of the lungs that is caught outside of hospital); - complicated infections of the skin and the soft tissues below the skin.
Uporablja se lahko za zdravljenje spodnjih bakterijskih okužb: - izvenbolnišnično pridobljena pljučnica (okužba pljuč, do katere ne pride v bolnišnici), - zapletene okužbe kože in mehkih podkožnih tkiv.
The active substance in Octegra solution for infusion, moxifloxacin, belongs to the group ‘fluoroquinolones'.
Zdravilna učinkovina zdravila Octegra raztopina za infundiranje, moksifloksacin, spada v skupino „fluorokinolonov“.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Octegra solution for infusion outweigh its risks, and the marketing authorisation granted in Germany can be recognised in other Member States of the EU, namely France and Portugal.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da koristi zdravila Octegra raztopina za infundiranje odtehtajo njegova tveganja in da se lahko dovoljenje za promet z zdravilom, odobreno v Nemčiji, prizna tudi v drugih državah članicah Evropske unije, in sicer v Franciji in na Portugalskem.
The CHMP also recommended that the product information for the medicine should be amended in all the Member States where it is authorised.
CHMP je prav tako priporočil, da se informacije o zdravilu dopolnijo v vseh državah članicah, kjer je zdravilo odobreno.
Octegra solution for infusion is an antibiotic given by infusion (drip into a vein).
Zdravilo Octegra raztopina za infundiranje je antibiotik, ki se daje z infuzijo (kapalno infuzijo v veno).
Complicated means that the infection is difficult to treat because it has spread to the deep tissues below the skin, treatment with surgery might be needed, or the patient has other conditions that might affect the response to treatment.
ker se je razširila na globoka tkiva pod kožo, zato bo morda potreben operativni poseg, ali pa so pri bolniku prisotna druga stanja, ki lahko vplivajo na odziv na zdravljenje.
Why was Octegra solution for infusion reviewed?
Zakaj je bilo zdravilo Octegra raztopina za infundiranje pregledano?
Company responses provided on: 26 January 2009; 27 April 2009; 28 May 2009 Opinion date:
26. januar 2009; 27. april 2009; 28. maj 2009
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Octegra solution for infusion outweigh its risks, and therefore the marketing authorisation for Octegra solution for infusion should be granted in all concerned Member States.
CHMP je na podlagi ocenjevanja trenutno razpoložljivih podatkov in znanstvenih razprav zaključil, da koristi zdravila Octegra raztopina za infundiranje odtehtajo z njim povezana tveganja, zato se odobri dovoljenje za promet z zdravilom Octegra raztopina za infundiranje v vseh zadevnih državah članicah.
The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Octegra solution for infusion.
Evropska agencija za zdravila je po nesoglasju med državami članicami Evropske unije glede odobritve zdravila Octegra raztopina za infundiranje zaključila postopek arbitraže.
However, the prescribing information for Octegra solution for infusion should be amended in all the Member States where it is authorised.
Vendar je treba dopolniti podatke o predpisovanju zdravila Octegra raztopina za infundiranje v vseh državah članicah, kjer je odobreno.
What is Octegra solution for infusion?
Kaj je zdravilo Octegra raztopina za infundiranje?
The Committee recommended that:
Odbor je priporočil, da:
20 February 2013
20. februarja 2013
It was authorised in October 2008 and is available in 11 EU member states1.
Odobreno je bilo oktobra 2008 in je na voljo v 11 državah članicah EU1.
Outcome of procedures under Article 20 of Regulation (EC) No 726/2004 and Article 31 of Directive 2001/83/EC
Izid postopkov v skladu s členom 20 Uredbe (ES) št. 726/2004 in členom 31 Direktive 2001/83/ES.
1 Austria, Denmark, Estonia, France, Finland, Germany, Ireland, Netherlands, Spain, Sweden and United Kingdom, as well as Norway.
Ukrepi so vključevali spremembe informacij o zdravilu, v katerih je 1 Avstrija, Danska, Estonija, Francija, Finska, Nemčija, Irska, Nizozemska, Španija, Švedska in Združeno kraljestvo ter Norveška.
This indicates that the risk minimisation measures have not been sufficient.
Iz tega je razvidno, da ukrepi za zmanjšanje tveganja niso zadostni.
The solution is currently sprayed using either pressurised air or carbon dioxide (CO2).
Trenutno se raztopina naprši z zrakom pod tlakom ali ogljikovim dioksidom (CO2).
The European Commission issued a decision for Evicel on 13 February 2013 and for Quixil on 20 February 2013.
Evropska komisija je sklep o zdravilu Evicel izdala 13. februarja 2013, sklep o zdravilu Quixil pa 20. februarja 2013.
At the same time, the UK's medicines regulatory agency requested the CHMP to carry out the same assessment for Quixil and the other fibrin sealants available in the EU.
Istočasno je agencija Združenega kraljestva za zdravila zaprosila CHPM, naj opravi podobno presojo za zdravilo Quixil in druga fibrinska lepila, ki so na voljo v EU.
• the wording for the product information should be strengthened and educational materials updated to provide clear and consistent information to surgeons on the recommended pressure and distance during spray application;
• je treba okrepiti besedilo informacij o zdravilu in posodobiti izobraževalno gradivo, da se kirurgom zagotovijo jasne in dosledne informacije o priporočenem tlaku in razdalji med pršenjem;
The Committee also agreed that the company marketing these medicines should provide a letter to relevant healthcare professionals in the EU explaining these risk minimisation measures.
Odbor se je prav tako strinjal, da morajo podjetja, ki imajo dovoljenje za promet s temi zdravili, zadevnim zdravnikom v EU poslati dopis z obrazložitvijo teh ukrepov za zmanjšanje tveganja.
In addition, care should be taken during laparoscopy (another type of less invasive surgical procedure) to ensure that the minimum safe distance from the tissues is observed;
Poleg tega je treba posebej paziti med laparoskopijo (drugo vrsto manj invazivnega kirurškega posega), da se zagotovi upoštevanje najmanjše varne razdalje od tkiva;
Consequently, in May 2012, the European Commission asked the CHMP to issue an opinion on whether further measures are necessary to ensure the safe use of Evicel and on whether its marketing authorisation should be maintained, varied, suspended or withdrawn across the EU.
Evropska komisija je zato maja 2012 CHMP pozvala, naj predloži svoje mnenje o tem, ali je treba za zagotovitev varne uporabe zdravila Evicel uvesti nadaljnje ukrepe, in o tem, ali se lahko dovoljenje za promet za to zdravilo v EU ohrani ali pa ga je treba spremeniti, začasno umakniti oziroma preklicati.
• these medicines should not be sprayed in endoscopic surgery (a type of less invasive surgical procedure).
• teh zdravil ni dovoljeno napršiti pri endoskopskem posegu (vrsti manj invazivnega kirurškega posega).
The full changes made to the product information for Evicel are detailed here, and for Quixil here.
Celotne spremembe informacij o zdravilu Evicel so na voljo tukaj in o zdravilu Quixil tukaj.
The CHMP noted that fibrin sealants have the potential to be life-saving in certain circumstances, and that applying these medicines by spray is considered to be of benefit when there is a large surface area of bleeding during certain surgical procedures.
CHMP je opozoril, da lahko fibrinska lepila v določenih okoliščinah rešijo življenje in da je nanos teh zdravil s pršenjem koristen, kadar gre za krvavenje iz večje površine med določenimi kirurškimi posegi.
The CHMP reviewed available safety data on fibrin sealants from clinical studies, post-marketing use and the published literature, focusing on reported cases of confirmed or suspected gas embolism.
CHMP je pregledal razpoložljive varnostne podatke o fibrinskih lepilih iz kliničnih študij, podatke o uporabi zdravila po izdaji dovoljenja za promet in podatke iz objavljene literature, pri čemer se je osredotočil na opisane primere potrjene ali domnevne plinske embolije.
In August 2010, measures were taken to minimise the risk of gas embolism (presence of a gas bubble in the blood that affects the blood flow) following five reported cases involving Evicel or Quixil applied
Avgusta 2010 so bili sprejeti ukrepi za zmanjšanje tveganja za plinsko embolijo (prisotnost plinskih mehurčkov v krvi, ki vplivajo na krvi obtok), potem ko so o njej poročali v petih primerih po nanosu zdravila Evicel ali Quixil s pršenjem.
The CHMP is still reviewing four other fibrin sealants: Tisseel, Tissucol, Artiss and Beriplast P (and associated names).
CHMP še zmeraj presoja štiri druga fibrinska lepila: Tisseel, Tissucol, Artiss in Beriplast P (in povezana imena).
However, since then, three further cases of gas embolism have been reported with Evicel, which were due to insufficient distance between the applicator and tissue or too high spray pressure.
Vendar so po tem poročali še o treh primerih plinske embolije po uporabi zdravila Evicel, do katerih je prišlo zaradi nezadostne razdalje med pršilnikom in tkivom ali previsokega pršilnega tlaka.
On 15 November 2012, the European Medicines Agency completed a review of the safety and effectiveness of the fibrin sealants Evicel and Quixil given by spray application, following cases of gas embolisms reported with these medicines.
Evropska agencija za zdravila je 15. novembra 2012 zaključila pregled varnosti in učinkovitosti fibrinskih lepil Evicel in Quixil za pršenje, ki je bil sprožen zaradi primerov plinske embolije pri uporabi teh zdravil.
The CHMP also noted that, although cases of gas embolism are rare, there is a need to take further measures to prevent this life-threatening risk.
CHMP je prav tako poudaril, da je treba kljub redkim primerom plinske embolije sprejeti nadaljnje ukrepe za preprečitev smrtno nevarnega tveganja.
• the company for Evicel and Quixil should ensure that these products are used with pressure regulators that do not exceed the maximum pressure required to deliver the fibrin sealant, and that contain labels stating the recommended pressure and distance.
• mora podjetje za zdravila Evicel in Quixil zagotoviti, da se zdravila uporabljajo z regulatorji tlaka, ki ne presegajo največjega tlaka, dovoljenega za nanos fibrinskih lepil, in da sta na nalepkah izdelkov navedena priporočeni tlak in priporočena razdalja.
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Evicel and Quixil continue to outweigh their risks, but that further risk minimisation measures should be implemented when these medicines are given by spray application to ensure that they are used correctly.
Na osnovi ocene trenutno razpoložljivih podatkov in znanstvene razprave v Odboru je CHMP zaključil, da koristi zdravil Evicel in Quixil še zmeraj odtehtajo z njima povezana tveganja, vendar je treba uvesti nadaljnje ukrepe za zmanjšanje tveganja pri nanosu zdravil s pršenjem, da bi zagotovili njihovo pravilno uporabo.
• Surgeons should note the potential risk of gas embolism with improper spray application of Evicel and Quixil and take the necessary precautions detailed in the updated prescribing advice for these medicines.
• Kirurgi naj upoštevajo morebitno tveganje za plinsko embolijo pri neustreznem pršenju zdravil Evicel in Quixil in izvajajo potrebne varnostne ukrepe, opredeljene v posodobljenih navodilih o predpisovanju teh zdravil.
Evicel is the only centrally authorised fibrin sealant.
Zdravilo Evicel je edino fibrinsko lepilo, odobreno po centraliziranem postopku.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines given by spray application continue to outweigh their risks, but that appropriate measures have to be put in place to minimise the risk of gas embolism.
Odbor za zdravila za uporabo v humani medicini (CHMP) Evropske agencije za zdravila je sklenil, da koristi zadevnih zdravil za pršenje še zmeraj odtehtajo z njimi povezana tveganja, vendar je treba sprejeti ustrezne ukrepe za zmanjšanje tveganja za plinsko embolijo.
They are composed of two solutions, one containing fibrinogen and the other containing thrombin, which are both proteins involved in the blood clotting process.
Sestavljena so iz dveh raztopin, od katerih ena vsebuje fibrinogen, druga pa trombin.
The fibrin then aggregates (sticks together) and forms a fibrin clot that helps the wound to heal, stopping the bleeding.
Fibrini se nato združijo (medsebojno zlepijo) in ustvarijo fibrinski strdek, ki pomaga ozdraviti rano, saj ustavi krvavenje.
• Evicel or Quixil application by spray should only be considered if it is possible to accurately judge the spraying distance.
• Zdravilo Evicel ali Quixil naj se naprši samo v primeru, ko je mogoče ustrezno presoditi razdaljo pršenja.
• Evicel and Quixil should be sprayed using CO2 only.
• Zdravili Evicel in Quixil naj se napršita samo s CO2.
• Spraying Evicel or Quixil in endoscopic surgery is contraindicated.
• Nanos zdravila Evicel ali Quixil s pršenjem pri endoskopskem posegu je kontraindicirana.
Fibrin sealants can be applied by dripping or spraying the solution onto bleeding tissue.
Fibrinska lepila se lahko nanesejo s kapljanjem ali pršenjem raztopine na krvaveče področje.
Other fibrin sealants in the EU are authorised nationally and these include Quixil, Tisseel, Tissucol, Artiss and Beriplast P (and associated names).
Mednje spadajo zdravila Quixil, Tisseel, Tissucol, Artiss in Beriplast P (in povezana imena).
• Evicel and Quixil should be sprayed using CO2 only, instead of pressurised air, because the greater solubility of CO2 in blood reduces the risk of embolism;
• se zdravili Evicel in Quixil namesto z zrakom pod tlakom napršita samo s CO2, saj večja topnost
These included changes to the product information to specify the maximum spray pressure to use during application and the recommended distance from the tissue surface.
določen največji pršilni tlak med nanosom zdravila ter priporočena razdalja od površine tkiva.
It has been authorised in 24 EU Member States.
Odobreno je v 24 državah članicah EU.
These measures should help to protect the environment.
Takšni ukrepi bodo pomagali varovati okolje.
Hungary Zoetis Hungary Kft. Alkotás u. 53.
Madžarska Zoetis Hungary Kft. Alkotás u. 53.
The symptoms disappeared within 5 to 8 days without interruption of the treatment.
Spremembe izginejo v 5 do 8 dneh, brez prekinitve zdravljenja.
Contact with skin and eyes should be avoided.
Treba se je izogibati stiku s kožo in očmi.
There is no evidence that this situation is evolving.
Dokazov o nadaljnjem razvoju tega stanja ni.
A fresh solution should be prepared each day.
Svežo raztopino je treba pripraviti vsak dan.
The first marketing authorisation was granted in 1972.
Prvo dovoljenje za promet z zdravilom je bilo odobreno leta 1972.
This might be due partly to natural resistance.
To je lahko delno posledica naravne odpornosti.
Via Andrea Doria, 41 M 00192 Roma Italy
Via Andrea Doria, 41 M 00192 Roma Italija
Human and animal bacteria share the same resistance determinants.
Človeške in živalske bakterije imajo enake determinante odpornosti.
Care should be taken not to raise and inhale any dust.
Paziti je treba, da se ne dviguje in vdihuje prahu.
EC4A 3AE London United Kingdom
EC4A 3AE London Združeno Kraljestvo
This evaluation focuses on issues in regards to the harmonisation that may change the benefit-risk balance.
Ta ocena se osredotoča na težave, povezane z uskladitvijo, ki bi lahko spremenile razmerje med tveganji in koristmi.
Discussion of data available
Razprava o razpoložljivih podatkih
Moreover the harmonised dosing regimen is the one recommended in a vast majority of the Member States.
Poleg tega je usklajeni režim odmerjanja eden od priporočenih v večini držav članic.
Treatment should be initiated as soon as first clinical signs occur.
Z zdravljenjem je treba začeti takoj, ko se pojavijo prvi klinični znaki.
* The restriction of the indications to those that are adequately substantiated by efficacy data;
• omejitvijo indikacij na zadostno utemeljene s podatki o učinkovitosti;
Medicated water should be removed every day and replaced by a new solution.
Medicirano vodo je treba vsak dan odstraniti in zamenjati z novo raztopino.
* The deletion of all recommendations for prophylactic use;
• izbrisom vseh priporočil, povezanih s profilaktično uporabo;
150 g of powder = 100 g antibiotic activity should be diluted in…
150 g praška = 100 g aktivnosti antibiotika je treba raztopiti v…
The oral absorption of lincomycin was found to be 53% ± 19%.
Ugotovljena peroralna absorpcija linkomicina je bila med 53 % ± 19 %.
Excipients: For the full list of excipients, see section 6.1.
Pomožne snovi: Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
Also, as the dosing regimens and indications have not been extended, there is no change in the assessment of user safety.
Ker se režimi odmerjanja in indikacije niso razširili, prav tako ni spremembe pri oceni varnosti za uporabnika.
Regarding B. hyodysenteriae, including the points already mentioned, several issues were identified:
Glede B. hyodysenteriae so bile ugotovljene mnoge težave (vključno z že omenjenimi):
Overall summary of the scientific evaluation of LincoSpectin 100 and its associated names (see Annex I)
Splošni povzetek znanstvenega vrednotenja zdravila LincoSpectin 100 in povezanih imen (glejte Prilogo I)
Moreover L. intracellularis, like Brachyspira spp.
Poleg tega je L. intracellularis tako kot Brachyspira spp.
PROHIBITION OF SALE, SUPPLY AND/OR USE To be completed nationally.
PREPOVED PRODAJE, OSKRBE IN/ALI UPORABE Podatke je treba dopolniti v posameznih državah.
Sick animals have a reduced appetite and an altered drinking pattern, and severely affected animals may therefore require parenteral treatment.
Bolne živali imajo zmanjšan apetit in spremenjen vzorec pitja in hudo prizadete živali bodo zaradi tega morda potrebovale parenteralno zdravljenje.
In the challenge study the bacterial infection seemed to be eradicated.
V provokacijski študiji je bilo videti, da je bila bakterijska okužba izkoreninjena.